Clinical trials are an important way to improve treatment for people with cancer. While most are continuing during the COVID-19 pandemic, the period of time that clinical trials are available and recruiting may change quickly. If you would like to get involved in a clinical trial, speak to your treatment team or the health service where the clinical trial is being undertaken, to confirm it is open and appropriate for you. For cancer information and support, call Cancer Council's experienced cancer nurses on 13 11 20 Monday to Friday from 9am-5pm.

Latest Trials

Systemic therapy trial

COLUMBUS-AD : Adjuvant Encorafenib & Binimetinib vs. Placebo in Fully Resected Stage IIB/C BRAF V600E/K...

This phase III study is evaluating how safe and effective combination targeted therapy (Encorafenib and Binimetinib), compared to a targeted therapy combined with a placebo (Binimetinib and placebo), is in people with melanoma who have had prior surgery

Status : Recruiting

Systemic therapy trial

BAT : A Phase 1, Multi-Center, Open-Label Study to Assess Safety, Tolerability,...

This phase I study is seeking to determine the best dose level and safety of a new targeted therapy (BAT6021) alone, and in combination with another targeted therapy (BAT1308), in people with locally advanced, recurrent, or metastatic incurable solid cancers

Status : Recruiting

Multiple treatment types

SKYSCRAPER : A Phase II, Open-Label, Multicenter Study Evaluating the Safety and Efficacy of...

This phase II study is evaluating how safe and effective combination immunotherapy (atezolizumab + tiragolumab) is alone, or in addition to chemotherapy, as neoadjuvant therapy in people with previously untreated locally advanced non-small cell lung cancer

Status : Recruiting

Systemic therapy trial

A Phase I/II, First-in-Human, Open-Label, Multicenter Study Evaluating the Safety,...

This phase I/II study is trying to determine the appropriate dose level, and safety, of a new targeted therapy (GB263T) in people with advanced solid cancer, including non-small cell lung cancer

Status : Recruiting

Systemic therapy trial

A Phase I/II, First-in-Human (FIH), Open-Label, Dose Escalation and Expansion Study to...

This phase I/II study is trying to determine how safe and effective, and what the appropriate dose level of a new cancer drug (LM-108) alone, or in combination with targeted therapy (an Anti-PD-1 Antibody) in people with solid cancers

Status : Recruiting

Systemic therapy trial

HLX301 : A Phase 1/2 Study of HLX301, A Recombinant Humanized Anti-PDL1 and Anti-TIGIT Bispecific...

This phase I/II study is seeking to determine the appropriate dose level, safety and effectiveness of a new cancer treatment (HLX301) in people with locally advanced or metastatic solid cancers

Status : Recruiting

Systemic therapy trial

A Phase 2 Open-Label, Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Adult...

This Phase II is trying to understand safe and effective a new cancer drug (ZN-c3) is in people with recurrent or persistent uterine serous carcinoma

Status : Recruiting

Systemic therapy trial

TALAPRO-3 : TALAPRO-3: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, STUDY OF TALAZOPARIB WITH ENZALUTAMIDE...

This Phase III trial is evaluating how safe and effective a targeted therapy (talzoparib) is in combination with hormone therapy (enzalutamide), compared to a placebo, in people with DDR-deficient metastatic castration-sensitive prostate cancer

Status : Recruiting

Systemic therapy trial

BOUQUET : A Phase II, Open-Label, Multicenter, Platform Study Evaluating the Efficacy and Safety of...

This phase II study is evaluating how safe and effective multiple biomarker-selected treatments are in people with persistent or recurrent rare epithelial ovarian, fallopian tube, or primary peritoneal cancer.

Status : Recruiting

Systemic therapy trial

YH004002 : A First-In-Human, Multicenter, Open-Label, Phase I Dose Escalation Study To Evaluate The...

This phase I study is seeking to determine the best dose level and effectiveness of a new targeted therapy (YH004) alone, and in combination with immunotherapy (toripalimab) in people with advanced solid cancers and relapsed or refractory non-Hodgkin lymphoma

Status : Recruiting

 

Looking for a trial? Use the search functionality to find the trial you are finding.